Polpharma Group B.V. https://www.polpharmagroup.com Helping people to live a healthy life in a healthy world Wed, 03 Jul 2024 07:54:26 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.1 https://www.polpharmagroup.com/wp-content/uploads/2022/02/cropped-sygnet-32x32.png Polpharma Group B.V. https://www.polpharmagroup.com 32 32 Polpharma celebrates 10 years of successful investments in Kazakhstan https://www.polpharmagroup.com/polpharma-celebrates-10-years-of-successful-investments-in-kazakhstan/ Wed, 29 Jun 2022 15:45:06 +0000 https://www.polpharmagroup.com/?p=11813
Astana Tms

POLPHARMA
CELEBRATES 10 YEARS
OF SUCCESSFULL
INVESTMENTS
IN KAZAKHSTAN

<  Return to News & Media Coverage

29 June 2022

29 June 2022

POLPHARMA
CELEBRATES 10 YEARS
OF SUCCESSFULL
INVESTMENTS
IN KAZAKHSTAN

Astana Tms

<  Return to News & Media Coverage

Polpharma Group has been making a significant contribution to the pharmaceutical industry’s development in Kazakhstan. The company’s input has demonstrated its vital role in the country during the pandemic.

Chairman of ZF Polpharma, Jerzy Starak, spoke about the company’s projects in the country and its development plans in a recent interview with The Astana Times. Read the interview below:

Poland’s Polpharma Celebrates 10 Years of Successful Investments in Kazakhstan

]]> Polpharma Group rigorously applies all sanctions towards Russia https://www.polpharmagroup.com/polpharma-group-rigorously-applies-all-sanctions-towards-russia/ Mon, 28 Mar 2022 12:36:32 +0000 https://www.polpharmagroup.com/?p=11798

Polpharma Group
rigorously applies
all sanctions
towards Russia

28 March 2022

<  Return to News & Media Coverage

28 March 2022

Polpharma Group rigorously applies all sanctions towards Russia

<  Return to News & Media Coverage

Polpharma Group respects and applies rigorously all sanctions concerning the Russian Federation put in place by the relevant authorities and the European Union especially. Moreover, we have decided to stop all new investments in Russia and to limit deliveries to the Russian Federation to life-altering drugs only. The restrictions put in place by the international community consider pharmaceuticals as a special category of goods which must be made available for all who need them, irrespective of nationality or race, especially a child or elderly patient. In turn, the entities producing them have an ethical responsibility which goes beyond that of other fields of industry. This point of view has been consistently adhered to in regard to sanctions imposed by the international community in the past and continues to be the common understanding of our industry.

Polpharma Group, through its subsidiaries, has and continues to donate hundreds of thousands of packages of life-altering medicines, including antibiotics and emergency medicines which are most lacking in hospitals in Ukraine. Many of our sites and offices collect donations, which are passed on to those in need through charitable organizations.

]]> Markus Sieger, CEO Polpharma Group, joins the Medicines for Europe as Vice President https://www.polpharmagroup.com/markus-sieger-ceo-polpharma-group-joins-the-medicines-for-europe-as-vice-president/ Fri, 11 Mar 2022 11:32:32 +0000 https://www.polpharmagroup.com/?p=11750

MARKUS SIEGER,
CEO POLPHARMA
GROUP, JOINS
MEDICINES FOR
EUROPE AS
VICE PRESIDENT

<  Return to News & Media Coverage

11 March 2022

11 March 2022

MARKUS SIEGER, CEO POLPHARMA GROUP, JOINS MEDICINES FOR EUROPE AS VICE PRESIDENT

<  Return to News & Media Coverage

Markus Sieger, CEO Polpharma Group, has been appointed to the position of Vice President of Medicines for Europe whose members represent the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries.

As member of Executive and Vice President, Markus Sieger will be working together with new President Elisabeth Stampa (Medichem) and Vice President Rebecca von Gunten (Sandoz) – on facilitating sustainable API and medicines manufacturing in the EU to secure affordable product supplies for patients, which are directly linked with the public health needs in Europe.

“Millions of European patients have and will benefit from better access to standard therapies because of the use of generic and biosimilar medicines today. Generic medicines have become the cornerstone of European healthcare drugs, proven by the recent COVID crisis. We have to secure that all essential medicines and API are produced here in Europe to secure access for years to come. Medicines for Europe and its activities are more important than ever. I will personally engage strongly into all aspects of digitalisation of the healthcare infrastructure, including the regulatory systems, e-leaflets etc. All in the interest of providing more affordable and better solutions to patients.”

Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added companies. As a leading partner for better healthcare, aim to increase the health and wellbeing of all Europeans through better access to high quality medicines. Medicines for Europe members’ portfolio cover 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations. Medicines for Europe’s ambition is fully aligned with the EU’s pharmaceutical and industrial strategy which shall be complemented by fast and efficient application of digital solutions both in medical care and health system management.

Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio.

See all members of Medicines for Europe: https://www.medicinesforeurope.com/medicines-for-europe/#section-5

]]> Solidarity with Ukrainian people https://www.polpharmagroup.com/solidarity-with-ukraine/ Fri, 04 Mar 2022 15:57:01 +0000 https://www.polpharmagroup.com/?p=11704

SOLIDARITY WITH UKRAINIAN PEOPLE

4 March 2022

<  Return to News & Media Coverage

4 March 2022

SOLIDARITY WITH UKRAINE

<  Return to News & Media Coverage

In connection with the ongoing war on the territory of Ukraine, we would like to express our deepest compassion and solidarity with the suffering nation of this country. With great sadness and agitation we observe the worsening tragic situation for the Ukrainian civilians and we, together with our employees, are committed to provide our support to them, including the supply of the most necessary life-saving medicines.

We provide help to people who are sick and in need wherever it is necessary, continuing providing help to the Ukrainian residents. First of all, we focus our efforts on ensuring the safety of our employees in Ukraine, helping them and their families relocate to Poland and providing the necessary support.

Polpharma donated several hundred thousand packages of life-saving medicines, including antibiotics and emergency medicines which are most lacking in hospitals in Ukraine. Many of our sites and offices collect donations, which are passed on to those in need through charitable organizations.

At Polpharma Group, we believe that every patient in need, especially a child or elderly patient, irrespective of race or nationality, has the right to access to the treatment. Taking into account the scope of sanctions imposed on the Russian Federation, which do not apply to medicines as means of protecting human health and life, we continue local production of medicines at JSC Akrikhin plant in Russia, operating within our Polpharma Group B.V. Other group companies supply only pediatric products, products used in acute medical conditions and chronic diseases to Russia.

]]> Markus Sieger, CEO Polpharma Group, joins the CEO Advisory Committee established by IGBA https://www.polpharmagroup.com/ceo-polpharma-group-joins-the-ceo-advisory-committee/ Thu, 17 Feb 2022 13:18:02 +0000 https://www.polpharmagroup.com/?p=11634

Markus Sieger, CEO Polpharma Group, joins the CEO Advisory Committee established by IGBA

The Committee, composed of CEOs of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States was established by the International Generic and Biosimilar medicines Association (IGBA) to provide a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues.

“This is the first time that the generic and biosimilar medicines industry’s company leadership has united in a structured framework, enabling a collective voice in the global pharmaceutical space”, said Vivian Frittelli, IGBA Chair.

Suzette Kox, IGBA Secretary General added “This industry has clearly lived up to the challenges posed by the pandemic. In many instances, there is now clear recognition that the generic and biosimilar medicines industry is the answer for affordable and sustainable solutions in such situations and beyond. It is vital that generic, biosimilar and value-added medicines now become central to global healthcare policies”.

This vision of the role of our industry in the global healthcare system is shared by Markus Sieger, CEO Polpharma Group. “To help people live a healthy life in a healthy world, I will strongly contribute to this Committee in areas such as patient compliance and other aspects of healthcare with digital and other innovative solutions” – commented Markus.

See all members of the CEO Advisory Committee: 

Members of the IGBA CEO Advisory Committee 2022 >>>

The International Generic and Biosimilar Medicines Association (IGBA) was founded in March 1997 as an international network of generic medicines associations. IGBA strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The association maintains constant dialogue with other national, regional and international bodies.

]]> 1935 https://www.polpharmagroup.com/1935-2/ Sun, 23 Jan 2022 18:07:46 +0000 http://fp1.pl/?p=11541

A Polish Chemical and Pharmaceutical Plant “Polpharma” was established in Starogard Gdanski.

]]> 1945 https://www.polpharmagroup.com/1945-2/ Sun, 23 Jan 2022 18:06:07 +0000 http://fp1.pl/?p=11535

Polpharma was nationalised. Two chemists Zygmunt Gmaj and Jerzy Sumczynski – become the managers of the facility.

]]> 1951 https://www.polpharmagroup.com/1951-3/ Sun, 23 Jan 2022 18:04:38 +0000 http://fp1.pl/?p=11529

The company started the production of sulfathiazole a popular bacteriostatic drug.

]]> 1951 https://www.polpharmagroup.com/1951-2/ Sun, 23 Jan 2022 18:02:10 +0000 http://fp1.pl/?p=11523

The plant’s name was charged to “Starogardzkie Zaklady Farmaceutyczne”.

]]> 1959 https://www.polpharmagroup.com/1959-2/ Sun, 23 Jan 2022 17:57:25 +0000 http://fp1.pl/?p=11518

The company was incorporated into the Pharmaceutical Industry Union “Polfa”.

]]>